Close Menu
The Central Wire
  • Home
  • News
  • Editorial
  • Business
  • Sci-Tech
  • Entertainment
  • Sports
  • Opinion
  • Markets
  • Automotive
  • Lifestyle
  • Tech Reviews
Facebook
The Central WireThe Central Wire
Subscribe
Thursday, June 5
  • Home
  • News
  • Editorial
  • Business
  • Sci-Tech
  • Entertainment
  • Sports
The Central Wire
  • Home
  • News
  • Editorial
  • Business
  • Sci-Tech
  • Entertainment
  • Sports
Home - Daily Science - Dengue’s Enigma: A Surprising Shield Against COVID’s Onslaught?

Dengue’s Enigma: A Surprising Shield Against COVID’s Onslaught?

Daily Science 30/06/2024Basanta Kumar SahooBy Basanta Kumar Sahoo3 Mins Read

A Viral Paradox: Dengue Antibodies and Coronavirus Protection:

In a surprising twist of fate, antibodies produced to combat dengue, a mosquito-borne viral illness prevalent in India, may hold the key to understanding why the initial COVID-19 wave in the country was less devastating compared to regions where dengue is not endemic. This intriguing revelation stems from research conducted at the CSIR-Indian Institute of Chemical Biology, where scientists explored the interaction between dengue antibodies and a surrogate coronavirus called murine hepatitis virus (MHV).

Unveiling the Mechanism: Neutralizing the Enemy:

The study, published in the Journal of Medical Virology, revealed that dengue antibodies can effectively “neutralize” MHV, a virus belonging to the same family as human coronaviruses and often used as a model to study their behavior. This neutralization occurs through a process where dengue antibodies bind to and “mask” the surface of coronaviruses, preventing them from entering susceptible cells.

A Complex Dance of Immunity:

While the research offers a glimmer of hope, it also raises a plethora of questions. The dengue virus family is distinct from coronaviruses, and infection with one does not typically confer protection against the other. Moreover, there are four major serotypes of dengue, and infection with one does not necessarily shield against the others. In fact, re-infection with a different serotype can sometimes exacerbate the disease, a phenomenon known as antibody-dependent enhancement (ADE).

Unraveling the Epidemiological Puzzle:

The researchers posit that the prevalence of dengue in Southeast Asia, including India, may have influenced the evolution of the coronavirus, potentially triggering new mutations. They also highlight the curious observation that dengue cases declined in India during the early stages of the COVID-19 pandemic, a phenomenon that warrants further investigation.

A Double-Edged Sword: Cross-Reactivity and Antibody-Dependent Enhancement:

The interplay between dengue and COVID-19 immunity remains a complex and multifaceted puzzle. The presence of cross-reactive antibodies raises the question of whether they offer partial protection against both diseases or whether they could lead to increased severity due to ADE. Larger, multicentric clinical studies are needed to fully understand this intricate relationship.

A Glimmer of Hope Amidst Uncertainty:

While the research findings are preliminary, they offer a tantalizing glimpse into the potential role of pre-existing dengue immunity in mitigating the severity of COVID-19. If confirmed, this discovery could have profound implications for vaccine development and public health strategies, particularly in regions where dengue is endemic.

Conclusion:

The research from the CSIR-Indian Institute of Chemical Biology has opened a new avenue of inquiry into the complex interplay between dengue and COVID-19. While many questions remain unanswered, the findings suggest a potential link between pre-existing dengue immunity and reduced COVID-19 severity. This intriguing possibility warrants further investigation and could ultimately lead to novel approaches for combating both diseases.

Basanta Kumar Sahoo
Basanta Kumar Sahoo

Basant Kumar Sahoo is a seasoned writer with extensive experience in crafting tech-related articles, insightful editorials, and engaging sports content. With a deep understanding of technology trends, a knack for thought-provoking commentary, and a passion for sports, Basant brings a unique blend of expertise and creativity to his writing. His work is known for its clarity, depth, and ability to connect with readers across diverse topics.

antibodies antibody-dependent enhancement COVID-19 cross-reactivity dengue epidemiology immunity vaccine development virus neutralization
Previous ArticleCovaxin’s Intellectual Property Conundrum: Unveiling the Storm Behind Bharat Biotech’s Admission
Next Article OnePlus Pad Pro: A Powerful Leap in Tablet Technology

Keep Reading

Asteroid 2024 PT5 Becomes Earth’s Mini-Moon for 56 Days

New Antibody SC27 Targets Covid Variants with Breakthrough Potency

Battle Against Asian Hornets: An Urgent Mission to Protect the UK’s Ecosystem

DMCA.com Protection Status
World At a Glance

Ireland Hate Speech Law Shelved After Controversy

22/09/2024

Russian Airstrike Hits Kharkiv, Injuring 12 Civilians

22/09/2024

Ukraine War: Russia Rejects Peace Talks in Diplomatic Blow

22/09/2024

France Right-Wing Government Rises Amid Political Deadlock

22/09/2024

Ukraine War: Allies’ Support Key to Victory, Zelenskyy Warns

22/09/2024
Trending Now

Armani/Caffè Debuts in Mumbai, Redefining Luxury Dining

13/09/2024

Friday the 13th: Superstition, History, and the Internet’s Obsession

13/09/2024

Paris Paralympics 2024: India’s Record 29 Medals Achieved

09/09/2024

All the Winners (and EGOTs) of the 2024 Creative Arts Emmys

09/09/2024

Gillian Anderson’s Evolution: From Iconic TV Star to Advocate for Women’s Sexual Liberation

09/09/2024
TCW LOGO
  • World Today
  • India Today
  • Sports
  • Entertainment
  • Business
  • Gadgets Review
  • Car Review
  • Bike Review
  • Mobile Review
  • Tablet review
  • Editorials
  • Opinion
  • Editor's Choice
  • Explained
  • Trending Now
© 2025 The Central Wire or its affiliated companies. All rights reserved.
  • Privacy Policy
  • Terms
  • About Us
  • Contact Us

Type above and press Enter to search. Press Esc to cancel.